Floatz logo

VENLOR

Breast Neoplasm

Evgen PharmaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

40 Active assets in the Breast Neoplasm cohort.

Asset / SponsorPhaseRating
Zofran
Umeå University
Phase 4BB
Inno-206
Merck Sharp & Dohme LLC
Phase 2BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 2BB
Sv-Br-1-Gm
BriaCell Therapeutics Corporation
Phase 3BB
ROPIVACAINE
Karlstad Central Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

VENLOR is also rated in:

depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
major depressive disorderDormant
BB
Indicative ·
71 / 100
View asset →
VenlafaxineDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →